Three-dose Hepatitis B Vaccine Regimen Protects People with HIV

A three-dose course of the hepatitis B vaccine HEPLISAV-B fully protected adults living with HIV who had never been vaccinated against or infected with the hepatitis B virus (HBV), according to study findings presented today at the IDWeek conference in Washington, D.C. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsors the ongoing Phase 3 ACTG A5379 clinical study. HBV is spread primarily through sexual contact and sharing of contaminated needles and can cause chronic hepatitis B infection and lead to progressive liver disease. People living with HIV, including those who are taking antiretroviral therapy, are at greater risk of liver-related illness and death when co-infected with HBV. Researchers tested a three-dose course of HEPLISAV-B, made by Dynavax Technologies, Corp., among 68 adults living with HIV at 38 sites in the United States, South Africa, and Thailand. Nearly all (98.5%) of the study participants developed protective antibodies against HBV. The international study, which continues to examine the effects of two-dose HEPLISAV-B and a three-dose regimen of another hepatitis B vaccine, is expected to complete vaccinations in March 2023. Read the NIAID release here: http://bitly.ws/vF3J.   Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107